← Back to all trials
Active Not Recruiting
NCT05742087
Neuropathy and Anti-GFAP Antibodies
Conditions: Neurological Diseases or Conditions, Neurological Diseases Associated to Anti GFAP Antibodies
Sex: All
Ages: 18 Years – N/A
Enrollment: 120
Sponsor: Hospices Civils de Lyon
Location: France
Summary
Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system.
The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells.
Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS).
Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts.The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.
Eligibility Criteria
Inclusion Criteria:- Age > 18 years oldNeurological symptomsAnti-GFAP antibodies identified in the CSFExclusion Criteria:- Uncomplete data in the medical records of patients
Source: ClinicalTrials.gov (NCT05742087). StuddyBuddy aggregates publicly available trial information.